Viridian Therapeutics (STU:1S1) 3-Year EBITDA Growth Rate : 16.10% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viridian Therapeutics 3-Year EBITDA Growth Rate?

Viridian Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was €-0.94.

During the past 3 years, the average EBITDA Per Share Growth Rate was 16.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 32.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Viridian Therapeutics was 69.00% per year. The lowest was -309.10% per year. And the median was 33.10% per year.

Competitive Comparison of Viridian Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Viridian Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Viridian Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Viridian Therapeutics (STU:1S1) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Viridian Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

VRDN:USA 0K1R:UK

Address

221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines